1/9
08:51 am
apvo
Aptevo Therapeutics jumps after securing $60 million equity line of credit [Seeking Alpha]
Medium
Report
Aptevo Therapeutics jumps after securing $60 million equity line of credit [Seeking Alpha]
1/9
08:13 am
apvo
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality [Yahoo! Finance]
High
Report
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality [Yahoo! Finance]
11/12
01:24 pm
apvo
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
11/10
08:18 am
apvo
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors [Yahoo! Finance]
Medium
Report
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors [Yahoo! Finance]
11/7
01:12 am
apvo
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.